The primary objective of this study is to evaluate the efficacy and safety of CDP6038
administered subcutaneous (sc) at various doses compared to placebo.
Biological: Olokizumab 60 mg
Biological: Olokizumab 120 mg
Biological: Olokizumab 240 mg
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01463059
Ages eligible for Study
20 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Have a diagnosis of adult-onset RA of at least 6 months' (24 weeks) duration as defined by the 1987 ACR classification criteria or a score of ≥6 as defined by the ACR/European League Against Rheumatism Classification and Diagnostic Criteria for RA
Must have moderately to severely active RA disease as defined by ≥6 tender joints
(68-joint count) at Screening and Baseline, ≥6 swollen joints (66-joint count) at Screening and Baseline, CRP ≥1.2 times the upper limit of normal (ULN) or ESR
Must be on an MTX dose of 6 to 16mg/week in Japan or 7.5 to 20mg/week in Korea and Taiwan, which has been stable for at least 6 weeks prior to Screening with a stable route of administration
Must have had intolerance or inadequate response to treatment with 1 or more TNF-blocker therapies within 2 years of Screening
Female subjects must be either postmenopausal for at least 1 year, surgically incapable of childbearing, or effectively practicing 2 acceptable methods of contraception
Have a diagnosis of any other inflammatory arthritis
Female subjects who are breast-feeding, pregnant, or plan to become pregnant during the study or within 24 weeks
Disease modifying antirheumatic drug (DMARDs) other than methotrexate (MTX)
Subjects with known concurrent acute or chronic viral hepatitis B or C infection
Subject has known tuberculosis (TB) disease, high risk of acquiring TB infection, or latent TB infection
Subjects with known history of or current clinically active infection
Subjects at high risk of infection
Subjects with known human immunodeficiency virus (HIV) or human T cell lymphotropic virus type 1 (HTLV 1) infection
Have received vaccinations within 8 weeks prior to Screening or plan to receive vaccines during the study (with the exception of injectable influenza and pneumococcal vaccinations which are permitted)
Concurrent malignancy or a history of malignancy (with the exception of successfully treated carcinoma of the cervix more than 5 years prior to Screening or no more than 2 successfully treated basal cell carcinomas within 2 years prior to Screening
All locations for NCT01463059
Korea, Republic of (6)
Daejeon, Korea, Republic of
Gangnam-Gu, Korea, Republic of
Jung-gu, Korea, Republic of
Seongdong-gu, Korea, Republic of
Seoul, Korea, Republic of
Seoul, Korea, Republic of
View full eligibility
Tris trial is registered with FDA with number: NCT01463059. The sponsor of the trial is UCB Japan Co. Ltd. and it is looking for 119 volunteers for the current phase.
Official trial title: A Randomized, Double-blind, Placebo Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of CDP6038 Administered Subcutaneously for 12 Weeks to Asian Subjects With Active Rheumatoid Arthritis Having Previously Failed TNF Blocker Therapy
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.